ArticleInternational journal of clinical oncology2026
Effect of Vonoprazan, potassium-competitive acid blocker, on Atezolizumab plus Bevacizumab efficacy in patients with hepatocellular carcinoma: a multicenter retrospective study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How should we interpret the use of vonoprazan and proton pump inhibitors during immunotherapy for hepatocellular carcinoma?International journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProton pump inhibitors (PPIs) have received considerable attention as inducers of gut dysbiosis through gastric acid suppression. PPI-induced gut dysbiosis is associated with a poor prognosis in patients with non-small cell lung cancer and urothelial cancer treated with immune checkpoint inhibitors (ICIs), but not in those with hepatocellular carcinoma (HCC). Although vonoprazan, which showed more powerful acid suppression than PPIs, tended to decrease efficacy in non-small cell lung cancer and urothelial cancer, its effect on ICIs therapy for HCC remains unknown and was evaluated in this study.
methodsThis multicenter retrospective study included patients aged ≥ 18 years with HCC who received atezolizumab plus bevacizumab (Atz/Bev) between September 2020 and December 2023 at five hospitals. The primary and secondary endpoints were differences in progression-free survival (PFS) and overall survival (OS), respectively.
resultsOf the 354 eligible patients, 115 received PPIs, 55 received vonoprazan, and 184 received neither vonoprazan nor PPIs (non-gastric acid suppression [GAS] group). In the multivariate analysis, compared to vonoprazan group, there were no significant differences in the PFS of the PPI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.73-1.53; P = 0.77) and non-GAS groups (HR, 0.93; 95% CI, 0.65-1.32; P = 0.67). Similarly, there were no significant differences in the OS of PPI (HR, 0.94; 95% CI, 0.59-1.48; P = 0.78) and non-GAS groups (HR, 0.75; 95% CI, 0.48-1.17; P = 0.20).
conclusionVonoprazan was not associated with worse PFS and OS in patients with HCC treated with Atz/Bev than in those who did not receive PPIs and neither.
Indexed as
Identifiers
41240182What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.